Study of Nivolumab in Subjects With Relapsed or Refractory Follicular Lymphoma (FL) (CheckMate 140)
NCT02038946
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
116
Enrollment
INDUSTRY
Sponsor class
Conditions
Lymphoma
Interventions
DRUG:
Nivolumab
Sponsor
Bristol-Myers Squibb